The company has recorded zero revenue across the last ten quarters, while recent net losses of $4.2 million in 2026Q1 appear artificially constrained by the cessation of clinical programs rather than operational success.
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 138K | 0 |
| Revenue Growth % | - | - | - | - | - | -100% | - | - |
| Cost of Goods Sold | 24K | 534K | 0 | 0 | 5.99M | 0 | 0 | 20K |
| COGS % of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | -24K | -534K | 0 | 0 | -5.99M | 0 | 138K | -20K |
| Gross Margin % | - | - | - | - | - | - | 100% | - |
| Gross Profit Growth % | - | - | - | 100% | - | -100% | 790% | - |
| Operating Expenses | 54.01M | 52.37M | 73.54M | 159.17M | 200.18M | 155.56M | 33.78M | 6.58M |
| OpEx % of Revenue | - | - | - | - | - | - | 24479.71% | - |
| Selling, General & Admin | 23.46M | 27.22M | 44.21M | 47.55M | 62.23M | 51.31M | 14.38M | 2.56M |
| SG&A % of Revenue | - | - | - | - | - | - | 10422.46% | - |
| Research & Development | 20.04M | 10M | 11.84M | 39.6M | 141.06M | 107.25M | 19.4M | 4.03M |
| R&D % of Revenue | - | - | - | - | - | - | 14057.25% | - |
| Other Operating Expenses | 988K | 15.15M | 17.49M | 72.01M | -3.11M | -3M | 0 | 0 |
| Operating Income | -54.04M | -52.91M | -73.54M | -159.17M | -206.17M | -155.56M | -33.64M | -6.58M |
| Operating Margin % | - | - | - | - | - | - | -24379.71% | - |
| Operating Income Growth % | - | 28.06% | 53.8% | 22.8% | -32.53% | -362.37% | -410.92% | - |
| EBITDA | -53.75M | -52.37M | -69.93M | -154.41M | -200.18M | -152.81M | -33.39M | -6.57M |
| EBITDA Margin % | - | - | - | - | - | - | -24194.2% | - |
| EBITDA Growth % | 29.91% | 25.11% | 54.71% | 22.86% | -31% | -357.67% | -408.58% | - |
| D&A (Non-Cash Add-back) | 291K | 534K | 3.61M | 4.76M | 5.99M | 2.75M | 256K | 20K |
| EBIT | -45.25M | -52.91M | -66.14M | -151.87M | -223.37M | -155.27M | -33.64M | -6.52M |
| Net Interest Income | -2.13M | -1.97M | -2M | 3.66M | 1.77M | 80K | 70K | 68K |
| Interest Income | 3.36M | 3.86M | 6.99M | 8.87M | 3.65M | 80K | 70K | 68K |
| Interest Expense | 5.49M | 5.83M | 8.99M | 5.21M | 1.88M | 0 | 0 | 0 |
| Other Income/Expense | 6.66M | -18.46M | -594K | 3.08M | -19.08M | -1.2M | -3.94M | 63K |
| Pretax Income | -47.38M | -71.37M | -74.14M | -156.09M | -225.25M | -156.75M | -37.59M | -6.52M |
| Pretax Margin % | - | - | - | - | - | - | -27236.96% | - |
| Income Tax | 0 | 0 | 0 | 0 | -2.07M | 39K | 151K | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0.92% | -0.02% | -0.4% | 0% |
| Net Income | -47.38M | -71.37M | -74.14M | -156.09M | -223.18M | -156.79M | -37.74M | -6.45M |
| Net Margin % | - | - | - | - | - | - | -27346.38% | - |
| Net Income Growth % | 39.29% | 3.73% | 52.5% | 30.06% | -42.34% | -315.48% | -484.72% | - |
| Net Income (Continuing) | -47.38M | -71.37M | -74.14M | -156.09M | -223.18M | -156.79M | -37.74M | -6.52M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -6.99 | -10.70 | -11.39 | -24.00 | -34.46 | -29.60 | -5.89 | -1.01 |
| EPS Growth % | 40.85% | 6.06% | 52.54% | 30.35% | -16.42% | -402.55% | -483.17% | - |
| EPS (Basic) | - | -10.70 | -11.39 | -24.00 | -34.46 | -29.60 | -5.89 | -1.01 |
| Diluted Shares Outstanding | 6.78M | 6.67M | 6.51M | 6.5M | 6.48M | 5.3M | 6.41M | 6.41M |
| Basic Shares Outstanding | 6.78M | 6.67M | 6.51M | 6.5M | 6.48M | 5.3M | 6.41M | 6.41M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
Imminent liquidity exhaustion
As indicated by the company's historical financial statements, Instil Bio has recorded zero revenue across the last ten quarters, reflecting its status as a pre-commercial clinical-stage entity that has yet to validate its Co-Z platform through any form of product sales or meaningful partnership-driven milestone payments.
The absence of top-line growth underscores the company's reliance on external capital markets rather than operational cash flow. Investors should note that without a commercialized product or a strategic licensing agreement, the revenue trajectory remains stagnant, leaving the firm entirely dependent on its dwindling cash reserves.
Based on reported figures, the company has successfully reduced its quarterly SG&A expenses from a peak of $11.4 million in 2024Q1 to $5.3 million by 2026Q1, suggesting a concerted effort to extend the remaining cash runway through significant headcount and operational footprint reductions.
This contraction in overhead appears to be a reactive measure to the lack of clinical progress and capital market access. While the reduction in spending is necessary for survival, it may also limit the firm's ability to execute on its remaining R&D pipeline, potentially creating a cycle of further operational stagnation.
According to recent SEC filings, the company's net losses have fluctuated significantly, with the 2026Q1 net loss of $4.2 million appearing artificially lower than previous periods, likely due to the impact of asset divestments and the cessation of various clinical programs rather than improved operational efficiency.
The volatility in net income suggests that the bottom line is currently driven by non-recurring restructuring items rather than core business performance. Analysts should monitor these figures closely, as the reported losses may not accurately reflect the underlying cash burn required to maintain the company's remaining clinical assets.
As reported in financial statements, the company's cash position has dwindled to approximately $6.6 million, a figure that warrants extreme caution given the historical quarterly burn rates which have frequently exceeded the current total cash balance in previous periods of active clinical development.
The current capital structure appears insufficient to support long-term R&D, suggesting that the company may be forced into highly dilutive financing or a distressed sale of its intellectual property. Investors should consider that the current valuation may be pricing in a liquidation scenario rather than a successful clinical outcome.
Quick answers to the most common questions about buying TIL stock.
For fiscal year 2025, Instil Bio, Inc. (TIL) reported total revenue of $0.0M.
Instil Bio, Inc. (TIL) reported a net loss of $71.4M for the fiscal year ending 2025.